ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Hospital Universitario 12 de Octubre
Madrid, Avenida de Cordoba S/n, Spain
- Clinica Universitaria de Navarra
Pío, Pamplona, Spain
- Hospital Clinico de Valencia
Ibanez, Valencia, Spain
- Hospital Universitario Vall D'Hebron
Barcelona, Spain
- Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
- Hospital Universitario Hm Sanchinarro Ciocc
Madrid, Spain
- Hospital Universitario Virgen del Rocio
Seville, Spain
- Name of Institution: Orlando Health Cancer Institute
Orlando, Florida, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Washington University - School of Medicine
St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Duke University Medical Center, Duke Cancer Institute
Durham, North Carolina, United States
- Ou Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- M.D. Anderson Cancer Center
Houston, Texas, United States
- Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Aug 2019
- Primary completion
- 23 Dec 2026
- Completion
- 30 Apr 2037
- Last update posted
- 7 Apr 2026
- Registered enrollment
- 120
- Registry id
- NCT04044859
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.